QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
OTCMKTS:PMCUF

Pro Medicus (PMCUF) Stock Forecast, Price & News

$42.00
+1.85 (+4.61%)
(As of 06/6/2023 ET)
Compare
Today's Range
$42.00
▼
$42.00
50-Day Range
$38.49
▼
$44.02
52-Week Range
$26.26
▼
$47.92
Volume
100 shs
Average Volume
708 shs
Market Capitalization
N/A
P/E Ratio
2,800.00
Dividend Yield
0.05%
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

PMCUF stock logo

About Pro Medicus (OTCMKTS:PMCUF) Stock

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Receive PMCUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter.

PMCUF Stock News Headlines

May 23, 2023 | appleinsider.com
iPhone 14 Pro
May 22, 2023 | cnet.com
10 Best MacBook Pro Alternatives for 2023
June 6, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
March 21, 2023 | markets.businessinsider.com
Bell Potter upgrades Pro Medicus Limited (PMCUF) to a Hold
February 23, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Inspire Medical Systems (INSP) and Pro Medicus Limited (OtherPMCUF)
February 16, 2023 | msn.com
Pro Medicus GAAP EPS of A$25.96, revenue of A$57.4B
February 15, 2023 | afr.com
Tech’s hottest stock Pro Medicus delivers jump in profit
January 24, 2023 | markets.businessinsider.com
Goldman Sachs Reaffirms Their Hold Rating on Pro Medicus Limited (PMCUF)
June 6, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
January 18, 2023 | benzinga.com
Pro Medicus Stock (OTC:PMCUF), Quotes and News Summary
December 11, 2022 | markets.businessinsider.com
Wilsons Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)
November 14, 2022 | finance.yahoo.com
Visage Leads with CloudPACS at RSNA 2022
August 19, 2022 | seekingalpha.com
Pro Medicus Limited (PMCUF) CEO Sam Hupert on Q4 2022 Results - Earnings Call Transcript
August 17, 2022 | fool.com.au
Pro Medicus share price fails to fly on 44% profit leap
July 21, 2022 | fool.com.au
Why has the Pro Medicus share price surged 32% in a month?
July 11, 2022 | finance.yahoo.com
Pro Medicus (ASX:PME) jumps 3.0% this week, though earnings growth is still tracking behind five-year shareholder returns
July 7, 2022 | fool.com.au
Why Goldman Sachs just upgraded Pro Medicus shares
June 26, 2022 | fool.com.au
The Pro Medicus share price is down 30% in 2022. Is it a buy?
June 13, 2022 | fool.com.au
Pro Medicus share price tumbles despite $47m contract renewal news
June 12, 2022 | finance.yahoo.com
Investors Shouldn't Overlook Pro Medicus' (ASX:PME) Impressive Returns On Capital
June 2, 2022 | fool.com.au
Broker tips Pro Medicus share price to shoot 25% higher
June 1, 2022 | afr.com
Shares to open lower; Pro Medicus signs contract with Allina
May 25, 2022 | finance.yahoo.com
Pro Medicus Limited (ASX:PME) Shares Could Be 33% Above Their Intrinsic Value Estimate
May 2, 2022 | fool.com.au
Why is the Pro Medicus share price sinking on Monday?
April 14, 2022 | finance.yahoo.com
Is Now The Time To Put Pro Medicus (ASX:PME) On Your Watchlist?
April 14, 2022 | finance.yahoo.com
Is Now The Time To Put Pro Medicus (ASX:PME) On Your Watchlist?
April 7, 2022 | fool.com.au
Pro Medicus share price jumps on $32m contract news
See More Headlines

PMCUF Price History

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Health Information Services
Sub-Industry
N/A
Sector
Computer and Technology
Current Symbol
OTCMKTS:PMCUF
CUSIP
N/A
CIK
N/A
Web
www.promed.com.au
Phone
61 3 9429 8800
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
2,676.67
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Sam Aaron Hupert M.B.B.S.
    M.D., Co-Founder, CEO, MD & Exec. Director
  • Mr. Anthony Barry Hall B.Sc.
    B.Sc.(Hons), M.Sc., Co-Founder, Technology Director & Exec. Director
  • Mr. Clayton James Hatch CPA
    B.Comm, CPA, CFO & Company Sec.
  • Dr. Malte Westerhoff
    GM of Europe & Global CTO
  • Mr. Brad Levin
    GM of North America & Global Head of Marketing
  • Mr. Sean Lambright
    Global Head of Sales - Visage Imaging Inc
  • Ms. Teresa Gschwind
    Global Head of Customer Service of Visage Imaging Inc.

Key Competitors

View All Competitors













PMCUF Stock - Frequently Asked Questions

Should I buy or sell Pro Medicus stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pro Medicus in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PMCUF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PMCUF, but not buy additional shares or sell existing shares.
View PMCUF analyst ratings or view top-rated stocks.

How have PMCUF shares performed in 2023?

Pro Medicus' stock was trading at $36.00 at the beginning of the year. Since then, PMCUF shares have increased by 11.5% and is now trading at $40.15.
View the best growth stocks for 2023 here.

Is Pro Medicus a good dividend stock?

Pro Medicus (OTCMKTS:PMCUF) pays an annual dividend of $0.02 per share and currently has a dividend yield of 1.63%. The dividend payout ratio is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

What is Pro Medicus' stock symbol?

Pro Medicus trades on the OTCMKTS under the ticker symbol "PMCUF."

How do I buy shares of Pro Medicus?

Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro Medicus' stock price today?

One share of PMCUF stock can currently be purchased for approximately $40.15.

How can I contact Pro Medicus?

Pro Medicus' mailing address is 450 Swan Street, Richmond, Victoria (VIC). The official website for the company is www.promed.com.au. The company can be reached via phone at 61 3 9429 8800.

This page (OTCMKTS:PMCUF) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -